Every 8-K that Molina Healthcare, Inc. (MOH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MOH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MOH filings page.
Molina Healthcare, Inc. reported second quarter 2026 GAAP diluted EPS of $1.19 and adjusted diluted EPS of $1.51, as total revenue reached $10.9 billion. GAAP net income was $60 million, a 76% year‑over‑year decrease, with consolidated MCR at 92.2% versus 90.4% a year earlier.
Premium revenue was $10.2 billion, a 6% year‑over‑year decrease, on membership of about 4.9 million. Operating cash flow for the first half of 2026 was $788 million compared with a $112 million outflow a year earlier, and days in claims payable were 44.
The company reaffirmed full‑year 2026 premium revenue guidance of about $42 billion and increased GAAP EPS guidance to at least $2.15 and adjusted EPS to at least $5.25 per diluted share. Guidance includes an estimated loss of $1.50 per share from the new Florida Medicaid contract and $1.00 per share related to exiting the traditional MAPD product.
Molina Healthcare, Inc. announced that the Illinois Department of Healthcare and Family Services intends to award a HealthChoice Illinois Medicaid Managed Care program contract to its subsidiary, Molina Healthcare of Illinois. The planned go-live date is January 1, 2027.
The contract is expected to run for four-and-a-half years, with an option for the state to extend it by up to an additional five-and-a-half years. Molina Healthcare of Illinois will be one of six health plans serving roughly 3.1 million total Medicaid beneficiaries in Illinois.
The announcement is forward-looking and subject to risks, including possible protests or legal actions, delays to the start date, or a shorter contract term than anticipated.
Molina Healthcare, Inc. reported results from its May 6, 2026 annual stockholder meeting. Stockholders approved an amendment to the 2025 Equity Incentive Plan, increasing the shares of common stock authorized for issuance by 1,500,000 shares to a total of 3,295,000 shares.
Investors also approved an amendment to the Certificate of Incorporation and related bylaw changes that allow stockholders holding at least 20% of the voting power, and meeting specified ownership and disclosure requirements, to request special meetings, subject to several limitations on repeat or overlapping agenda items.
All ten director nominees were elected and all five proposals passed, including advisory approval of named executive officer compensation and ratification of Ernst & Young LLP as independent auditor. The meeting had strong participation, with 47,172,628 shares represented, or 90.55% of the 52,091,073 shares outstanding as of the record date.
Molina Healthcare, Inc. filed a current report stating it is hosting an Investor Day conference on May 8, 2026, beginning at 9:30 a.m. Eastern Time. During the event, the company plans to share updates on its business, including long-term financial targets and strategic and operational plans.
The presentation used for Investor Day is provided as Exhibit 99.1 and is incorporated by reference. A live webcast and a 30-day online replay of the event will be available on the company’s investor relations website.
Molina Healthcare reported first quarter 2026 results with GAAP diluted EPS of $0.27 and adjusted diluted EPS of $2.35, both sharply below the prior year. Total revenue was $10.8 billion, with premium revenue of about $10.2 billion, down 4% year over year.
Results were heavily affected by a $93 million impairment tied to the planned 2027 exit of the Medicare Advantage-Part D product, driving GAAP net income down to $14 million from $298 million. The consolidated medical care ratio rose to 91.1%, while the G&A ratio increased to 7.2%.
The company served roughly 5.0 million members as of March 31, 2026 and generated operating cash flow of $1,082 million versus $190 million a year earlier. Management reaffirmed 2026 guidance for premium revenue of about $42 billion, GAAP EPS of at least $1.90, and adjusted EPS of at least $5.00.
Molina Healthcare reaffirmed its 2026 full-year earnings outlook ahead of upcoming investor meetings and a health care conference appearance. Management continues to expect at least $3.20 in GAAP diluted EPS and at least $5.00 in adjusted diluted EPS for 2026.
The company will present at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026, with a live webcast and 30‑day replay on its investor relations website. Molina also set dates for its first-quarter 2026 earnings release and call on April 22–23, 2026, and announced an Investor Day on May 8, 2026, both with live webcasts and 30‑day replays.
Molina Healthcare, Inc. amended its credit agreement on February 4, 2026, temporarily easing a key debt covenant. The required minimum quarterly interest coverage ratio was reduced from 3.00:1.00 to 1.75:1.00 for quarters ending March 31 through December 31, 2026, then stepped up to 2.00:1.00 for March 31, 2027, 2.50:1.00 for June 30, 2027, and 2.75:1.00 for September 30, 2027.
The company also determined on February 5, 2026 that it will record an estimated non-cash, pre-tax impairment charge of approximately $93 million in the first quarter of 2026, tied to certain intangible assets. This follows a decision to exit its Medicare Advantage Prescription Drug product for 2027 to focus exclusively on dual eligible Medicare members. The charge will be recorded outside of adjusted net income.
Molina Healthcare, Inc. filed a current report stating that it issued a press release with its financial results for the fourth quarter and year ended December 31, 2025, as well as full-year 2026 revenue and earnings guidance.
The press release is provided as Exhibit 99.1 to the report, and any information on the company’s website referenced in that release is expressly excluded from being part of this report.
Molina Healthcare, Inc. has completed a private offering of $850.0 million aggregate principal amount of 6.500% Senior Notes due 2031. These senior unsecured notes pay interest semi-annually on February 15 and August 15, starting August 15, 2026, and mature on February 15, 2031. The notes rank equally with Molina’s other senior unsecured debt, are subordinated to secured debt with respect to collateral, and are structurally subordinated to liabilities of its subsidiaries.
The notes are redeemable on and after December 15, 2027 at specified prices, and may be redeemed earlier with a make-whole premium. Holders receive a repurchase right upon a defined change of control. The notes were issued in a private offering without registration rights. Molina also entered into a new revolving credit agreement with Truist Bank and lenders, replacing its prior credit agreement with substantially similar terms but certain covenants amended in a manner favorable to the company.
Molina Healthcare, Inc. has priced $850 million of 6.500% senior notes due 2031 in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S. These notes are senior unsecured debt obligations of the company and are being sold in a transaction exempt from registration under the Securities Act, meaning they cannot be freely offered or sold in the United States without registration or an applicable exemption. The offering is expected to close on or about November 20, 2025, subject to customary closing conditions, and the company has issued a press release describing the pricing terms.
Molina Healthcare, Inc. (MOH) reported that it intends to privately offer $750 million of senior notes due 2031, with net proceeds expected to repay outstanding delayed draw term loans under its existing credit facility. After repayment, the company plans to terminate that facility and enter into a fully committed new revolving credit facility that will be undrawn at closing and available for general corporate purposes. Molina noted it currently has no borrowings under the existing facility and has sufficient cash on its balance sheet. To support potential note investors, Molina shared non-GAAP performance data, including EBITDA rising from $1,349 million in 2022 to $1,893 million in 2024 and Adjusted EBITDA increasing from $1,709 million in 2022 to $2,091 million in 2024, with intermediate periods also provided.
Molina Healthcare (MOH) reported that Florida’s Agency for Health Care Administration issued a Notice of Agency Decision stating its intent to award Molina Healthcare of Florida a contract to provide Statewide Medicaid Managed Care (SMMC) and Children’s Health Insurance Program (CHIP) services to enrollees of the Title XIX and Title XXI Children’s Medical Services (CMS) Program. The company furnished a press release as Exhibit 99.1.
Molina Healthcare (MOH) filed an 8-K announcing it released its financial results for the third quarter ended September 30, 2025 and updated its full-year 2025 earnings guidance. The company provided these details in a press release attached as Exhibit 99.1.
This is a routine disclosure under Item 2.02, directing readers to the press release for the specific results and guidance figures.
Molina Healthcare amended its existing credit facility to add a new Delayed Draw A-2 commitment of $500 million, creating a Term Loan A-2 that matures on August 12, 2027. The new tranche carries an applicable margin of 0.50% for base rate loans and 1.50% for SOFR-based loans and is substantially similar in other terms to the prior credit agreement.
The company states it will use the Term Loan A-2 proceeds to partially fund its previously authorized stock repurchase program as a temporary measure because of the timing of subsidiary dividends to the parent later this year. The amendment and related agreement are included as Exhibit 10.1, with certain schedules omitted from the public filing but available to the SEC upon request. This amendment creates a direct financial obligation under the Amended Credit Agreement.
Molina Healthcare, Inc. filed a Form 8-K on July 7, 2025 to furnish Item 2.02 information. The company has released a press release (Exhibit 99.1) containing preliminary, unaudited financial results for the second quarter of 2025 and an update to its full-year 2025 adjusted earnings-per-share guidance. No numerical data or qualitative detail is included in the 8-K itself; investors must review the attached press release for specifics. The disclosure is being furnished—not filed—so it is not subject to Section 18 liability or automatically incorporated into other SEC filings. Apart from customary exhibit listings (Exhibit 104 Inline XBRL cover page), the filing reports no other material events, transactions, or changes.